Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01898767 · ClinicalTrials.gov registry record
Eicosanoid Lipids by Airway Cells During Infection With Human Rhinoviruses
A clinical trial, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- 44
- Enrollment target
NCT01898767: Completed study, sponsored by University of Wisconsin, Madison.
NCT01898767 is a clinical trial that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 44 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01898767 has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- 44 participants
- Enrollment target
Study Summary
The long-range goal of this protocol is to more completely understand the risks and the pathophysiology of asthma exacerbations, in order to develop prevention strategies and/or expedite a return to complete control of baseline asthma symptoms.
Primary Outcome
P2X7 agonist-induced fold stimulation (over the media control) of cox2 expression (assessed by densitometry) in alveolar macrophages primed with conditioned medium from minor group HRV-infected epithelial cells.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2013-12-17 |
| Est. Completion | 2017-08-29 |
What the finished NCT01898767 record still lists
NCT01898767 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 44 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01898767 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01898767 about?
NCT01898767 is a clinical study titled "Eicosanoid Lipids by Airway Cells During Infection With Human Rhinoviruses". The long-range goal of this protocol is to more completely understand the risks and the pathophysiology of asthma exacerbations, in order to develop prevention strategies and/or expedite a return to complete control of baseline asthma symptoms.
What is the current status of trial NCT01898767?
This trial is currently completed. The enrollment target is 44 participants. The study started on 2013-12-17. Estimated completion is 2017-08-29.
Who is sponsoring clinical trial NCT01898767?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI